Supplemental
. Causal model for analyses, including treatment (the use of BMA), endpoints (SRE and overall survival), and confounders, as selected by clinical experts in myeloma. Supplemental Table S1 . Definition of claims-based covariates in the study. BMA: bone-modifying agents; HCPCS: Healthcare Common Procedure Coding System; ICD-9: International Classification of Diseases, 9 th revision; NDC: National Drug Code; SEER: Surveillance, Epidemiology, and End Results a to improve specificity, diagnostic codes had to be recorded at least once in inpatient claims, or at least twice, at least 30 days apart, in outpatient claims Supplemental Figure S4 . Propensity score analysis in the subcohort of patients who received bortezomib and/or an IMiD as part of their first-line regimen for myeloma.
(A) balance of confounders, as determined by standardized differences of means (SDM); SDM of <0.1 conventionally indicates sufficient balance; (B) cumulative incidence function (CIF) of skeletal-related events (SRE) in the propensity score-matched cohort (N=2,316); outcome model reports subhazard ratio (SHR) with 95% confidence interval (CI); (C) overall survival in the propensity score-matched cohort (N=2,316); outcome model reports hazard ratio (HR) with 95%CI. Figure S5 . Sensitivity analyses.
(A) estimate of subhazard ratio for the CIF of SRE, with 95% confidence interval (CI), after propensity score (PS) matching was conducted in subcohorts defined by progressively narrower ranges of allowed PS values; the estimate at 0% trim reproduces the main study result; as more % is trimmed, the number of matched pairs decreases, resulting in wider CI and increased mean bias; there was no evidence of a significant change in the estimate with higher trims; (B) OS estimate after analogous procedure; (C) a matrix showing estimates of subhazard ratio for the CIF of SRE, adjusted for an additional, unobserved, binary confounder, according to Lin et al.; 6 the confounder is simulated to have a hazard ratio of 2.0 ( ); if * is the baseline regression coefficient in the absence of the confounder, and and denote prevalence of the confounder among treated and untreated, then the adjusted coefficient ; the 95% CI around the adjusted coefficient was calculated using the delta method; blue squares indicate statistically significant results; panels (E), (F), (G), and (H) show analogous analyses conducted in the subpopulation of patients receiving a novel agent (bortezomib or IMiD) as part of their first-line regimen. Supplemental Table S2 . Sensitivity analysis for the time window of BMA administration from the start of first-line therapy. The results for all endpoints were consistent when the window was varied between 60 and 120 days from the start of chemotherapy. 
